Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells

Anticancer Research

Volumn 22, Issue 5, 2002, Pages 2597-2606

  Ohta, Koji ^a   Yamaguchi, Yoshiyuki ^a   Shimizu, Katsuhiko ^a   Miyahara, Eiji ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Carcinoembryonic antigen; Cytotoxic effector lymphocytes; Dendritic cells. T cell receptor; Interleukin

Indexed keywords

B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY CD3; RECEPTOR ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; KILLER CELL; LYMPHOCYTOTOXICITY; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; T LYMPHOCYTE; TARGET CELL; TUMOR IMMUNITY;

CARCINOEMBRYONIC ANTIGEN; CELLS, CULTURED; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENES, T-CELL RECEPTOR BETA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; STOMACH NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 0036765643     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shilini E and Vetto JT: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
2. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
3. Yamaguchi Y, Ohta K, Shimizu K, Minami K, Noma K, Hihara J and Toge T: Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin-2. Anticancer Res 21: 669-677, 2001.
4. Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2-lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80: 42-49, 1997.
5. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356: 802-807, 2000.
6. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD and Freeman SM: Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28: 321-331, 1997.
7. Ravaud A, Legrand E, Delaunay MM, Bussieres E, Coulon V, Cany L, Huet S, Verdier D, Kind M and Chomy F: A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Br J Cancer 71: 331-336, 1995.
8. Aruga A, Yamauchi K, Takasaki K, Furukawa T and Hanyu F: Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer 49: 19-24, 1991.
9. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991.
10. Van den Eynde BJ and Boon T: Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27: 81-86, 1997.
11. Mescher MF: Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Immunol Rev 146: 177-210, 1995.
12. Lanzavecchia A and Sallusto F: Regulation of T cell immunity by dendritic cells. Cell 106: 263-266, 2001.
13. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM and Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83-93, 1994.
14. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA and Kawakami Y: Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58: 4895-4901, 1998.
15. Miyahara E, Yamaguchi Y, Minami K, Hihara J, Noma K, Toge T, Takafuta T and Fujimura K: T-cell receptor V β gene usage of human cytotoxic T-cell clones obtained from gastric cancer patients. Anticancer Res 19: 2057-2066, 1999.
16. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM and Schlom J: Generation of human cytotoxic T cells specific for.human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87: 982-990, 1995.
17. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY and Schlom J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from hyman carcinoembrionic antigen. Cancer Res 57: 4570-4577, 1997.
18. Sekine T, Shiraiwa H, Yamazaki T, Tobisu K and Kakizoe, T: A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharmacother 47: 73-78, 1993.
19. Miyahara E, Yamaguchi Y, Hihara J, Noma K and Toge T: Profile of T-cell receptor V β gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions. J Exp Ther Oncol 1: 242-250, 1996.
20. Thompson JA, Gruner F and Zimmermann W: Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5: 344-366, 1991.
21. Kuroki M, Arakawa F, Khare PD, Kuroki M, Liao S, Matsumoto H, Abe H and Imakiire T: Specific targeting strategies of cancer gene therapy using a single-chain vairable fragment (scFv) with a high affinity for CEA. Anticancer Res 20: 4067-4071, 2000.
22. Kass E, Schlom J, Thompson J, Guadagni F, Grazinao P and Greiner JW: Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 59: 676-83, 1999.
23. Conry RM, Khazaeli MB, Saleh MN, Allen KO, Barlow DL, Moore SE, Crig D, Arani RB, Schlom J and LoBuglio AF: Phase I trial of a recombinant baccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneus administration. Clin Cancer Res 5: 2330-2337, 1999.
24. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK and Gilboa E: Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16: 364-369, 1998.
25. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA and Crystal RG: Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 186: 1247-1256, 1997.
26. Yamaguchi Y, Satoh Y, Miyahara E, Noma K, Funakoshi M, Takashima I, Sawamura A and Toge T: Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res 15: 2201-2206, 1995.
27. Howard CJ, Brooke GP, Werling D, Sopp P, Hope JC, Parsons KR and Collins RA: Dendritic cells in cattle: phenotype and function. Vet Immunol Immunopathol 72: 119-124, 199.
28. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG and Bedrosian 1: Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol 21: 157-178, 2001.
29. Schoenberger SP, Toes RE, van der Voort El, Offringa R and Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-3, 1998.
30. Romani N, Reider D, Heuer M, Ebner S, Kampgen E, Eibl B, Niederwieser D and Schuler G: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 196: 137-151, 1996.
31. Nakashima M, Sonoda K and Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 5: 938-942, 1999.
32. Wang J, Saffold S, Vao X, Krauss J and Chen W: Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161: 5516-5524, 1998.
33. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E and Vieweg J: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166: 2953-2960, 2001.
34. Alters SE, Gadea JR, Sorich M, O'Donoghue G, Talib S and Philip R: Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother 21: 17-26, 1998.
35. Cole DJ, Weil DP, Shamamian P, Rivoltini L, Kawakami Y, Topalian S, Jennings C, Eliyahu S, Rosenberg SA and Nishimura MI: Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res 54: 5265-5268, 1994.
36. Dunbar PR, Chen JL, Chao D, Rust N, Teisserenc H, Ogg GS, Romero P, Weynants P and Cerundolo V: Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol 162: 6959-6962, 1999.
37. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T and Coulie PG: High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 61: 3718-3724, 2001.
38. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Vrichard V and Boom T: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98: 10290-10295, 2001.